Comparative Pharmacology
Head-to-head clinical analysis: ACTICORT versus M PREDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICORT versus M PREDROL.
ACTICORT vs M-PREDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.
Methylprednisolone is a glucocorticoid receptor agonist. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of pro-inflammatory cytokines, chemokines, and adhesion molecules. It also inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.
4 to 48 mg/day orally or intramuscularly in divided doses every 12 hours; for acute conditions, up to 120 mg/day intravenously in divided doses every 4-6 hours.
None Documented
None Documented
1.5-2.5 hours; prolonged in hepatic impairment (up to 10 hours) and renal impairment (up to 6 hours)
Terminal elimination half-life: 2–4 hours. Clinical context: shorter than other corticosteroids; requires multiple daily doses for sustained anti-inflammatory effect.
Renal (70% as unchanged drug and metabolites), biliary/fecal (30%)
Primarily hepatic metabolism; <20% excreted unchanged in urine. Negligible biliary/fecal elimination.
Category C
Category C
Corticosteroid
Corticosteroid